Results 51 to 60 of about 1,917,601 (292)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

BMC Pulmonary Medicine, 2021
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease that is associated with severe uncontrolled eosinophilic asthma. Eosinophils play an important pathogenic role in the development of both diseases.
Carlos Martínez-Rivera, Ignasi Garcia-Olivé, Blanca Urrutia-Royo, Maria Basagaña-Torrento, Antoni Rosell, Jorge Abad   +5 more
doaj   +1 more source

Assessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthma

Biomedicines, 2022
Eosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such advances have been made for enhancing the control of ...
Crawford Currie, Bomi Framroze, Dave Singh, Simon Lea, Christian Bjerknes, Erland Hermansen   +5 more
doaj   +1 more source

Sputum autoantibodies in patients with severe eosinophilic asthma [PDF]

Journal of Allergy and Clinical Immunology, 2018
The persistence of eosinophils in sputum despite high doses of corticosteroids indicates disease severity in asthmatic patients. Chronic inflamed airways can lose tolerance over time to immunogenic entities released on frequent eosinophil degranulation, which further contributes to disease severity and necessitates an increase in maintenance ...
Manali, Mukherjee, David C, Bulir, Katherine, Radford, Melanie, Kjarsgaard, Chynna Margaret, Huang, Elizabeth A, Jacobsen, Sergei I, Ochkur, Ana, Catuneanu, Hanah, Lamothe-Kipnes, James, Mahony, James J, Lee, Paige, Lacy, Parameswaran K, Nair   +12 more
openaire   +2 more sources

Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey [PDF]

, 2018
Purpose: Severe asthma and asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) are difficult to control and are often associated with poor clinical outcomes.
이재현, Choon-Sik Park, Kim, MA, Kang, HR, Yeon-Mok Oh, Kim, MH, Hyouk-Soo Kwon, Tae-Bum Kim, An-Soo Jang, Park, HS, Park, HW, Oh, YM, Yoon, HJ, Kim, S, Kim, TB, Severe Asthma Work Group, the Korean Academy of Asthma, Allergy and Clinical Immunology, Byung-Jae Lee, Kwon, JW, null null, Joo-Hee Kim, Cho, SH, Kwang-Ha Yoo, Jae Hyun Lee, Sujeong Kim, Jang, AS, Jae-Woo Jung, 김민혜, Lee, JH, Kim, SH, 김상헌, So-Young Park, Kim, JH, Ban, GY, Sang-Heon Cho, Park, JS, Ho Joo Yoon, Jae-Woo Kwon, Ga-Young Ban, Kwon, HS, Jung, JW, Sang-Heon Kim, Heung-Woo Park, Ji Yong Moon, Hae-Sim Park, 윤호주, Yoo, KH, Jong-Sook Park, Cho, YS, Hye-Ryun Kang, Chan-Sun Park, Park, CS, Mi-Ae Kim, Min-Hye Kim, 문지용, You Sook Cho, Moon, JY, Lee, BJ, Park, SY   +57 more
core   +1 more source

Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Long‐term management strategies for severe chronic rhinosinusitis with nasal polyps (CRSwNP) increasingly include biologic therapy targeting Type 2 inflammation. However, data on outcomes after complete discontinuation of dupilumab following sustained disease control are scarce.
Patrick Huber, Manuel Lasch, Veronika Volgger, Clemens Stihl, Philipp Teupe, Fabienne Oettgen, Sophia Gantner, Moritz Gröger   +7 more
wiley   +1 more source

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion

Respiratory Medicine Case Reports, 2019
We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma.
Khodr Tello, Andreas Hoffmann, Björn Beutel, Timm Greulich, Claus Franz Vogelmeier, Manuel Jonas Richter, Stefan Kuhnert, Tobias Böselt, Peter Alter, Angelique Holland, Marco Idzko, Roland Buhl, Andreas Rembert Koczulla   +12 more
doaj   +1 more source

Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study

, 2022
Objective: Mepolizumab, an anti-interleukin 5 humanized monoclonal antibody, which is listed among the treatment options in the Global Initiative for Asthma 2020, is recommended as a step 5 therapy option for patients with uncontrolled severe ...
PAÇACI ÇETİN, GÜLDEN, NAZİK BAHÇECİOĞLU, SAKİNE, YILMAZ, İNSU, ARSLAN, BAHAR, ATAYIK, Emel, TURK, MURAT, GÜLMEZ, İNCİ   +6 more
core   +1 more source

Microbial‐Metabolite Signatures Are Associated With Glucocorticoid Responsiveness in Chronic Rhinosinusitis With Nasal Polyps

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) exhibit heterogeneous responses to oral glucocorticoids (GCs), but the biological basis of this variability remains unclear. Objective To identify gut microbiome‒plasma metabolomic signatures associated with GC responsiveness in CRSwNP patients and to compare their ...
Ying‐Ying Zhang, Xin‐Yu Ding, Mei‐Ping Lu, Yan‐Bing Chen, Ye Yuan, Lin Jiang, Min Zhang, Lei Cheng   +7 more
wiley   +1 more source

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

, 2017
Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma.
Anand Dalal, Saurabh Nagar, Bell, Christopher F., Forshag, Mark, Dalal, Anand, Nagar, Saurabh, CANONICA, GIORGIO, Basu, Anirban, Christopher F. Bell, Giorgio Walter Canonica, Mark Forshag, Anirban Basu, Steven W. Yancey, Yancey, Steven W   +13 more
core   +1 more source

Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan   +5 more
wiley   +1 more source